Core Viewpoint - MacroGenics, Inc. is set to present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, highlighting its focus on innovative antibody-based therapeutics for cancer treatment [1]. Company Overview - MacroGenics is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing monoclonal antibody-based therapeutics specifically for cancer treatment [3]. - The company utilizes a proprietary suite of next-generation antibody-based technology platforms, which are applicable across various therapeutic domains, to generate its pipeline of product candidates [3]. - MacroGenics has established several strategic collaborations with global pharmaceutical and biotechnology companies, leveraging its technology platforms and protein engineering expertise to create promising product candidates [3]. Event Information - The presentation at the Goldman Sachs conference will take place at 8:00 am ET in Miami, FL, and will be accessible via a webcast on the company's Investor Relations website [1][2]. - An archived replay of the webcast will be available on the company's website for 30 days following the event [2].

Core Viewpoint - MacroGenics, Inc. is advancing its clinical pipeline, particularly with the initiation of the Phase 2 LINNET study for lorigerlimab, targeting unmet needs in ovarian and gynecologic cancers, while also reporting financial results for Q1 2025 [1][2]. Clinical Development Updates - The first patient has been dosed in the LINNET Phase 2 study of lorigerlimab for platinum-resistant ovarian cancer and clear cell gynecologic cancer, with a focus on addressing significant unmet needs [2][7]. - The LORIKEET Phase 2 trial, involving 150 patients, is ongoing to evaluate lorigerlimab in combination with docetaxel for metastatic castration-resistant prostate cancer (mCRPC), with results expected in the second half of 2025 [6][7]. - MacroGenics is developing three antibody-drug conjugates (ADCs) in collaboration with Synaffix, including MGC026, MGC028, and MGC030, targeting various solid tumors [4][6]. Financial Performance - Total revenue for Q1 2025 was $13.2 million, an increase from $9.1 million in Q1 2024, primarily due to collaborative agreements and contract manufacturing [8][13]. - Research and development expenses decreased to $39.7 million in Q1 2025 from $46.0 million in Q1 2024, while selling, general and administrative expenses also fell to $10.7 million from $14.7 million [8][13]. - The net loss for Q1 2025 was $41.0 million, compared to a net loss of $52.2 million in Q1 2024, indicating improved financial performance [8][13]. Cash Position and Guidance - As of March 31, 2025, MacroGenics had cash, cash equivalents, and marketable securities totaling $154.1 million, down from $201.7 million at the end of 2024, which supports operations into the second half of 2026 [8][11]. - The company plans to implement cost-saving measures to extend its financial runway while continuing to progress its clinical pipeline [8][11].

Core Insights - VERAXA Biotech AG has announced a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced therapeutic discovery [1][2] - The collaboration is part of VERAXA's strategy to drive innovation through strategic partnerships, marking its second major initiative in six months [2] - Under the agreement, VERAXA will utilize OmniAb's transgenic antibody discovery solutions to source high-quality human antibody leads and will be responsible for preclinical validation of the bsADC lead candidate [2] Company Overview - VERAXA is focused on the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs and other innovative formats, leveraging transformative technologies and quality-by-design principles [3] - The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, emphasizing its commitment to pioneering life science research [3] Business Combination - On April 22, 2025, VERAXA entered into a definitive business combination agreement with Voyager Acquisition Corp., which is expected to lead to VERAXA becoming a publicly traded company on NASDAQ [4] - Voyager Acquisition Corp. aims to revolutionize the healthcare sector through strategic mergers and business combinations, supported by a team with extensive expertise in investing and medical innovation [5]

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models of Immune Checkpoint Failure Via Simultaneous Blockade of Neo-Angiogenesis" at the American Association for Cancer Research (AACR) Annual Meeting, from April 25–30, 2025, at the McCormick Place Co ...